Latest Long QT syndrome Stories
Reconstructing family trees dating back to 1811, Dutch researchers have estimated the death risk for people with inherited heart rhythm disorders, according to a study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. Heart rhythm disorders can result in sudden cardiac death in apparently healthy people because of severe disturbances in the rhythm of the heart. The risk is high for people who carry one of these rare genes and have symptoms such as...
Researchers have discovered a new link between the time of day and sudden cardiac death (SCD). Abnormal heart rhythms are the most common cause of sudden cardiac death, which happens most often in the morning hours, followed by a smaller peak during the evening hours. This phenomenon has been observed for years but doctors are just now beginning to understand the molecular reason. The researchers found that Krupple-like Factor 15 (KLF15) links the body’s circadian rhythm to the heart’s...
Poets might scoff at the notion that heart and brain are closely related, but scientists led by those at Baylor College of Medicine say a genetic defect that affects the brain can stop a heart. In a study published today in the journal Science Translational Medicine, BCM researchers and colleagues found that heart problems that occur in nearly 20 percent of children with Rett syndrome, a neurological disorder, originate because the Rett gene (MeCP2) is lost in nerve cells – not in heart...
ALISO VIEJO, Calif., Nov. 17, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) announced today that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect (PBA). Acceptance of the MAA confirms that the submission is sufficiently complete to permit a substantive review. NUEDEXTA was approved by the U.S. Food and Drug...
ALISO VIEJO, Calif., Oct. 18, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from clinical research activities will be highlighted at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Amsterdam, the Netherlands. ECTRIMS is considered the world's largest annual international conference devoted to basic and clinical research in multiple sclerosis. Following are...
ALISO VIEJO, Calif., Aug. 11, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that it has filed lawsuits in the U.S. District Court for the District of Delaware against Par Pharmaceutical, Inc. and Par Pharmaceutical Companies, Inc (collectively "Par") and Actavis South Atlantic LLC and Actavis, Inc. (collectively "Actavis"). The lawsuits were filed in response to Abbreviated New Drug Applications ("ANDAs") filed by Par and Actavis. In their applications,...
ALISO VIEJO, Calif., July 26, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced several positive developments regarding its anticipated European regulatory filing of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules for the treatment of pseudobulbar affect (PBA). On July 22, 2011, company officials met with the European Medicines Agency (EMA) to discuss plans for filing a marketing authorization application (MAA) for NUEDEXTA for...
The human genome encodes 243 voltage-gated ion channels. Mutations in calcium channels can cause severe inherited diseases such as migraine, night blindness, autism spectrum disorders and Timothy syndrome, which leads to severe cardiovascular disorders. Katrin Depil and Anna Stary-Weinzinger together with colleagues from the Department of Pharmacology and Toxicology, University of Vienna analyzed changes in molecular organization of calcium channels caused by Timothy syndrome mutations....
ALISO VIEJO, Calif., July 1, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA® (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on March 7, 2011. The company received Paragraph IV certification notices on June 30, 2011. Avanir intends to vigorously enforce its intellectual property...
ALISO VIEJO, Calif., May 16, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from a number of clinical research activities will be highlighted at the 164th Annual Meeting of the American Psychiatric Association (APA) taking place in Honolulu, HI, at the Hawaii Convention Center. Following are details about the data presentations: Title: The Safety of Dextromethorphan/Quinidine in Clinical Trial Participants Taking Selective Serotonin Reuptake...
